Harry Welten
Director Financiero/CFO en AFFIMED N.V. .
Fortuna: 73 200 $ al 30/04/2024
Origen de la red de primer grado Harry Welten.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Biotechnology | 20 | |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland.
17
| Extinct | Miscellaneous Commercial Services | 17 |
17
| Public Company | Biotechnology | 17 |
Arpida AG
 Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland.
12
| Extinct | Biotechnology | 12 |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.
8
| Subsidiary | Pharmaceuticals: Major | 8 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.
8
| Subsidiary | Miscellaneous Commercial Services | 8 |
ProteoMediX AG
 ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland.
7
| Subsidiary | Biotechnology | 7 |
Virometix AG
 Virometix AG Pharmaceuticals: MajorHealth Technology Virometix AG is a Swiss biotechnology company that focuses on developing vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. Virometix is based in Schlieren, CH. The private company's mission is to address the growing medical need for vaccines to combat infectious and chronic human diseases. The company was founded by John Anthony Robinson, and the CEO is Anna Sumeray.
4
| Private Company | Pharmaceuticals: Major | 4 |
Novaremed AG
 Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel.
2
| Holding Company | Pharmaceuticals: Major | 2 |
BioSupport AG
1
| Private Company | 1 | |
HBM Fondation
1
| Private Company | 1 | |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Harry Welten a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Founder Director/Board Member Director/Board Member Director/Board Member Chairman Director/Board Member | |
| University of Basel | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Undergraduate Degree | |
| University of Freiburg | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
| University of Zurich | College/University | Doctorate Degree Graduate Degree Masters Business Admin Undergraduate Degree | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member General Counsel Chief Executive Officer Director/Board Member | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member Director of Finance/CFO | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Chief Operating Officer Director/Board Member Chief Administrative Officer Chief Executive Officer | |
| EVOLVA HOLDING SA | Food: Specialty/Candy | Founder Director/Board Member Investor Relations Contact Chief Executive Officer | |
| FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| University of Bern | College/University | Undergraduate Degree Graduate Degree Doctorate Degree | |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Investment Managers | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member | |
| EPIGENOMICS AG | Medical Specialties | Director/Board Member Director/Board Member Chairman | |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Investment Managers | Director/Board Member Private Equity Investor Private Equity Investor | |
| University of Cambridge | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Undergraduate Degree Graduate Degree | |
Affimed NV Niederlassung Deutschland
 Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Corporate Officer/Principal Private Equity Investor | |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Chairman Director/Board Member Director/Board Member | |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Grenoble | College/University | Doctorate Degree Doctorate Degree | |
| GENTIUM S.P.A. (ADR) | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| CYMABAY THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| BIOINVENT INTERNATIONAL AB | Biotechnology | Director/Board Member Director/Board Member | |
| The University of Chicago | College/University | Undergraduate Degree Doctorate Degree | |
| CRISPR THERAPEUTICS AG | Biotechnology | Director/Board Member Director/Board Member | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Autolus Holdings (UK) Ltd.
 Autolus Holdings (UK) Ltd. BiotechnologyHealth Technology Part of Autolus Therapeutics Plc, Autolus Holdings (UK) Ltd. is a holding British company that operates subsidiaries engaged in pharmaceutical research and development activities. The company is based in London, UK and was founded in 2018. | Biotechnology | Director/Board Member Director/Board Member | |
| GAIN THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Founder | |
GT Gain Therapeutics SA
 GT Gain Therapeutics SA Pharmaceuticals: MajorHealth Technology GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
TOLREMO therapeutics AG
 TOLREMO therapeutics AG Miscellaneous Commercial ServicesCommercial Services TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Founder | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
venBio Partners LLC
 venBio Partners LLC Investment ManagersFinance venBio Partners LLC (venBio) is a private equity subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California. | Investment Managers | Founder Founder | |
| ONCONETIX, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
Sirius Healthcare Partners GmbH
 Sirius Healthcare Partners GmbH Investment ManagersFinance Sirius Healthcare Partners GmbH provides independent advice to small and mid-cap healthcare companies, venture capital firms, institutional and private investors. The firm's services include strategic advisory, mergers and acquisition and financing advisory. It serves in the area of biotechnology, medical technology and diagnostics, platform technologies and healthcare markets. The company was founded by Subhasis Roy, Khalid Islam, Ernesto Mancosu, Werner Tschollar, Andreas Vogler and Mikael von Euw and is headquartered in Zurich, Switzerland. | Investment Managers | Founder Founder | |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director of Finance/CFO Director/Board Member | |
| GIVAUDAN SA | Food: Specialty/Candy | Director of Finance/CFO Director of Finance/CFO | |
| BIOTEST AG | Pharmaceuticals: Other | Chairman Director/Board Member | |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA. | College/University | Corporate Officer/Principal Doctorate Degree | |
| University of Leiden | College/University | Doctorate Degree Undergraduate Degree | |
| University of London | College/University | Corporate Officer/Principal Doctorate Degree |
Estadísticas
Internacional
| Suiza | 15 |
| Estados Unidos | 15 |
| Alemania | 9 |
| Reino Unido | 9 |
| Países Bajos | 3 |
Sectorial
| Health Technology | 23 |
| Consumer Services | 14 |
| Finance | 8 |
| Commercial Services | 5 |
| Health Services | 3 |
Operativa
| Director/Board Member | 424 |
| Corporate Officer/Principal | 179 |
| Chairman | 110 |
| Independent Dir/Board Member | 84 |
| Founder | 75 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Annalisa Jenkins | 51 |
| Thomas Woiwode | 39 |
| Kurt von Emster | 34 |
| Jörg Neermann | 34 |
| Paul Brooke | 32 |
| Elmar Schnee | 31 |
| Khalid Islam | 29 |
| Gerhard Ries | 27 |
| Ferdinand Verdonck | 25 |
| John Berriman | 24 |
| Thomas O. Hecht | 24 |
| Thomas Dyrberg | 24 |
| Mathieu Simon | 22 |
| Vincent Ossipow | 22 |
| André L. Lamotte | 21 |
- Bolsa de valores
- Insiders
- Harry Welten
- Conexiones Empresas
